Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study.
Saved in:
| Title: | Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study. |
|---|---|
| Authors: | Ford CC; Department of Neurology, University of New Mexico Health Sciences Center, The University of New Mexico, Albuquerque, NM, USA., Cohen JA; Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic Foundation, Cleveland, OH, USA., Goodman AD; Department of Neurology, University of Rochester, Rochester, NY, USA., Lindsey JW; Department of Neurology, University of Texas Health Science Center at Houston (UTHouston), Houston, TX, USA., Lisak RP; Department of Neurology and Department of Biochemistry, Microbiology and Immunology, School of Medicine, Wayne State University, Detroit, MI, USA., Luzzio C; Departments of Neurology and Engineering, University of Wisconsin-Madison, Madison, WI, USA., Pruitt A; Department of Neurology, University of Pennsylvania Medical Center, Philadelphia, PA, USA., Rose J; Imaging and Neuroscience Center, School of Medicine, The University of Utah, Salt Lake City, UT, USA., Rus H; Department of Neurology, School of Medicine, University of Maryland, Baltimore, MD, USA., Wolinsky JS; Department of Neurology, University of Texas Health Science Center at Houston (UTHouston), Houston, TX, USA., Kadosh SE; Innovative Research and Development, Teva Pharmaceuticals, Netanya, Israel., Bernstein-Hanlon E; Global Clinical Programming, Teva Pharmaceuticals, Netanya, Israel., Stark Y; Global Clinical Development, Teva Pharmaceuticals, Netanya, Israel., Alexander JK; Global Medical Affairs, Teva Pharmaceuticals, West Chester, PA, USA/Jazz Pharmaceuticals, Palo Alto, CA, USA. |
| Source: | Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2022 Oct; Vol. 28 (11), pp. 1729-1743. Date of Electronic Publication: 2022 Jun 29. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-0970 (Electronic) Linking ISSN: 13524585 NLM ISO Abbreviation: Mult Scler Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 35768939 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Ford+CC%22">Ford CC</searchLink>; Department of Neurology, University of New Mexico Health Sciences Center, The University of New Mexico, Albuquerque, NM, USA.<br /><searchLink fieldCode="AU" term="%22Cohen+JA%22">Cohen JA</searchLink>; Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.<br /><searchLink fieldCode="AU" term="%22Goodman+AD%22">Goodman AD</searchLink>; Department of Neurology, University of Rochester, Rochester, NY, USA.<br /><searchLink fieldCode="AU" term="%22Lindsey+JW%22">Lindsey JW</searchLink>; Department of Neurology, University of Texas Health Science Center at Houston (UTHouston), Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Lisak+RP%22">Lisak RP</searchLink>; Department of Neurology and Department of Biochemistry, Microbiology and Immunology, School of Medicine, Wayne State University, Detroit, MI, USA.<br /><searchLink fieldCode="AU" term="%22Luzzio+C%22">Luzzio C</searchLink>; Departments of Neurology and Engineering, University of Wisconsin-Madison, Madison, WI, USA.<br /><searchLink fieldCode="AU" term="%22Pruitt+A%22">Pruitt A</searchLink>; Department of Neurology, University of Pennsylvania Medical Center, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Rose+J%22">Rose J</searchLink>; Imaging and Neuroscience Center, School of Medicine, The University of Utah, Salt Lake City, UT, USA.<br /><searchLink fieldCode="AU" term="%22Rus+H%22">Rus H</searchLink>; Department of Neurology, School of Medicine, University of Maryland, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22Wolinsky+JS%22">Wolinsky JS</searchLink>; Department of Neurology, University of Texas Health Science Center at Houston (UTHouston), Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Kadosh+SE%22">Kadosh SE</searchLink>; Innovative Research and Development, Teva Pharmaceuticals, Netanya, Israel.<br /><searchLink fieldCode="AU" term="%22Bernstein-Hanlon+E%22">Bernstein-Hanlon E</searchLink>; Global Clinical Programming, Teva Pharmaceuticals, Netanya, Israel.<br /><searchLink fieldCode="AU" term="%22Stark+Y%22">Stark Y</searchLink>; Global Clinical Development, Teva Pharmaceuticals, Netanya, Israel.<br /><searchLink fieldCode="AU" term="%22Alexander+JK%22">Alexander JK</searchLink>; Global Medical Affairs, Teva Pharmaceuticals, West Chester, PA, USA/Jazz Pharmaceuticals, Palo Alto, CA, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229509185%22">Multiple sclerosis (Houndmills, Basingstoke, England)</searchLink> [Mult Scler] 2022 Oct; Vol. 28 (11), pp. 1729-1743. <i>Date of Electronic Publication: </i>2022 Jun 29. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22SAGE+Publications%22">SAGE Publications </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9509185 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1477-0970 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2213524585%22">13524585 </searchLink><i>NLM ISO Abbreviation: </i>Mult Scler <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35768939 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1177/13524585221094239 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1729 Titles: – TitleFull: Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Ford CC – PersonEntity: Name: NameFull: Cohen JA – PersonEntity: Name: NameFull: Goodman AD – PersonEntity: Name: NameFull: Lindsey JW – PersonEntity: Name: NameFull: Lisak RP – PersonEntity: Name: NameFull: Luzzio C – PersonEntity: Name: NameFull: Pruitt A – PersonEntity: Name: NameFull: Rose J – PersonEntity: Name: NameFull: Rus H – PersonEntity: Name: NameFull: Wolinsky JS – PersonEntity: Name: NameFull: Kadosh SE – PersonEntity: Name: NameFull: Bernstein-Hanlon E – PersonEntity: Name: NameFull: Stark Y – PersonEntity: Name: NameFull: Alexander JK IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 10 Text: 2022 Oct Type: published Y: 2022 Identifiers: – Type: issn-electronic Value: 1477-0970 Numbering: – Type: volume Value: 28 – Type: issue Value: 11 Titles: – TitleFull: Multiple sclerosis (Houndmills, Basingstoke, England) Type: main |
| ResultId | 1 |